Fibrosarcoma Clinical Trials Fibrosarcoma RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Conditions:   Ewing Sarcoma;   Myxoid Liposarcoma;   Desmoplastic Small Round Cell Tumor;   Extraskeletal Myxoid Chondrosarcoma;   Angiomatoid Fibrous Histiocytoma;   Clear Cell Sarcoma;   Myoepithelial Tumor;   Low Grade Fibromyxoid Sarcoma;   Sclerosing Epithelioid Fibrosarcoma Intervention:   Drug: Seclidemstat Sponsor:   Salarius Pharmaceuticals, LLC Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2022 Category: Research Source Type: clinical trials